Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fauci says first U.S. COVID-19 vaccines could ship late December or early January

10/29/2020 | 01:36pm EST

CHICAGO, Oct 29 (Reuters) - If all goes well, the first doses of a safe and effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January, Dr. Anthony Fauci, the top U.S. infectious diseases expert, said on Thursday.

Based on current projections from vaccine front-runners Moderna Inc and Pfizer Inc, Americans will likely know "sometime in December whether or not we have a safe and effective vaccine," Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a live chat on Twitter and Facebook.

"The first interim look (at trial results) should be, we hope, within the next few weeks," he said.

Both companies started the final stage of clinical testing in late July with tens of thousands of people taking part in each trial.

Moderna earlier on Thursday said it was on track to deliver interim data from its large, late-stage trial next month.

Pfizer, which was expected to announce interim data in October, is now unlikely to release data before November, probably after the Nov 3. U.S. presidential election.

The data will then need to be reviewed by the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, which will make recommendations on who gets the first doses if the trials prove successful.

Practically speaking, Fauci said, the first vaccine doses would likely be deployed to individuals deemed most in need "by the end of December or the beginning of January."

Fauci's comments were part of a conversation with Dr. Francis Collins, director of the National Institutes of Health, who took questions from listeners.

Even with an effective vaccine to protect against the virus, Fauci said it will take time to get back to something approaching normal as vaccine-induced immunity builds both nationally and globally. He said life will likely not get back to normal "until the end of 2021 at least."

In the interim, Collins urged Americans to be prepared to continue wearing masks and maintain social distancing.

"I know Americans are tired of these measures. Tired of wearing masks. Tired of not being able to congregate together," Collins said. "But we've got a long road yet to go." (Reporting by Julie Steenhuysen Editing by Bill Berkrot)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
FACEBOOK INC 0.34% 287.52 Delayed Quote.39.61%
MODERNA, INC. 1.41% 143 Delayed Quote.620.91%
PFIZER, INC. 3.53% 40.8 Delayed Quote.6.17%
All news about MODERNA, INC.
04:18pNew York Will Get Enough Doses of Covid-19 Vaccine for 170,000 People -- 2nd ..
03:12pPFIZER, BIONTECH'S COVID-19 VACCINE : What You Need to Know
02:34pASTRAZENECA : As coronavirus soars, U.S. cheers Britain's vaccine approval
02:33pPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 5th Update
02:30pMODERNA : Canada review of Pfizer's coronavirus vaccine candidate should be done..
02:17pNew York Will Get Enough Doses of Covid-19 Vaccine for 170,000 People--Update
01:59pUK approves Pfizer-BioNTech COVID-19 vaccine in world first
01:50pREUTERS SUMMIT-Cowen's Solomon sees gains in biotech, helped by easier access..
01:03pPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 4th Update
11:05aHow the U.K. Beat the U.S. and Europe to a Covid-19 Vaccine
More news
Financials (USD)
Sales 2020 449 M - -
Net income 2020 -673 M - -
Net cash 2020 2 584 M - -
P/E ratio 2020 -95,6x
Yield 2020 -
Capitalization 55 799 M 55 799 M -
EV / Sales 2020 119x
EV / Sales 2021 7,40x
Nbr of Employees 1 100
Free-Float 90,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 114,35 $
Last Close Price 141,01 $
Spread / Highest target 31,2%
Spread / Average Target -18,9%
Spread / Lowest Target -57,4%
EPS Revisions
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.620.91%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.91.71%41 539
SEAGEN INC.55.27%31 988
IMMUNOMEDICS, INC.315.22%20 324